Latest & greatest articles for rheumatoid arthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rheumatoid arthritis

81. Effectiveness of an overall progressive resistance strength program for improving the functional capacity of patients with rheumatoid arthritis: a randomized controlled trial

Effectiveness of an overall progressive resistance strength program for improving the functional capacity of patients with rheumatoid arthritis: a randomized controlled trial 29050507 2017 10 20 1477-0873 31 11 2017 Nov Clinical rehabilitation Clin Rehabil Effectiveness of an overall progressive resistance strength program for improving the functional capacity of patients with rheumatoid arthritis: a randomized controlled trial. 1482-1491 10.1177/0269215517698732 To evaluate the effectiveness (...) of overall progressive resistance training in patients with rheumatoid arthritis. Randomized controlled clinical trial with blinded assessor and intention-to-treat analysis. Outpatient clinics. Sixty patients with rheumatoid arthritis according to the American College of Rheumatology criteria, aged between 18 and 65 years old, under stable medication and not performing regular physical activity were randomized into two groups: intervention group (IG) and control group (CG). IG performed the progressive

EvidenceUpdates2018

82. Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies

Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies 29095992 2017 11 02 1462-0332 2017 Oct 31 Rheumatology (Oxford, England) Rheumatology (Oxford) Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies. 10.1093/rheumatology/kex386 To evaluate the progression of erosions and joint space narrowing (JSN) in feet and hands (...) (Oxford) 100883501 1462-0324 Sharp/van der Heijde score methotrexate radiographic joint damage rheumatoid arthritis tocilizumab 2017 06 27 2017 11 3 6 0 2017 11 3 6 0 2017 11 3 6 0 aheadofprint 29095992 4583462 10.1093/rheumatology/kex386

EvidenceUpdates2018

83. Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial

Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial 29155973 2017 12 26 2017 12 26 1462-0332 57 1 2018 Jan 01 Rheumatology (Oxford, England) Rheumatology (Oxford) Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial. 84-91 10.1093/rheumatology/kex358 To explore whether tocilizumab + tapering MTX has comparable efficacy and safety vs (...) Arthritis, Rheumatoid drug therapy Double-Blind Method Drug Therapy, Combination Equivalence Trials as Topic Female Humans Male Methotrexate administration & dosage Middle Aged Treatment Outcome methotrexate rheumatoid arthritis tapering tocilizumab 2017 03 13 2017 11 21 6 0 2017 12 27 6 0 2017 11 21 6 0 ppublish 29155973 4396367 10.1093/rheumatology/kex358

EvidenceUpdates2018

84. A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis

A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis 28941039 2017 12 27 2326-5205 70 1 2018 Jan Arthritis & rheumatology (Hoboken, N.J.) A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis. 49-59 10.1002/art.40323 This 24-week, phase IIb, double-blind study was undertaken to evaluate the efficacy and safety of mavrilimumab (a monoclonal antibody to granulocyte-macrophage colony-stimulating factor receptor α) and golimumab (...) (a monoclonal antibody to tumor necrosis factor [anti-TNF]) in patients with rheumatoid arthritis (RA) who have had an inadequate response to disease-modifying antirheumatic drugs (DMARDs) (referred to as DMARD-IR) and/or inadequate response to other anti-TNF agents (referred to as anti-TNF-IR). Patients with active RA and a history of DMARD-IR (≥1 failed regimen) or DMARD-IR (≥1 failed regimen) and anti-TNF-IR (1-2 failed regimens) were randomized 1:1 to receive either mavrilimumab 100 mg subcutaneously

EvidenceUpdates2018

85. Physical Activity to Reduce Fatigue in Rheumatoid Arthritis: A Randomized Controlled Trial

Physical Activity to Reduce Fatigue in Rheumatoid Arthritis: A Randomized Controlled Trial 28378441 2017 12 23 2151-4658 70 1 2018 Jan Arthritis care & research Arthritis Care Res (Hoboken) Physical Activity to Reduce Fatigue in Rheumatoid Arthritis: A Randomized Controlled Trial. 1-10 10.1002/acr.23230 Effective treatments for rheumatoid arthritis (RA) fatigue are limited. We tested the effect of a pedometer-based intervention on increasing physical activity and decreasing fatigue among (...) United States Arthritis Care Res (Hoboken) 101518086 2151-464X 2016 07 31 2017 02 21 2017 4 6 6 0 2017 4 6 6 0 2017 4 6 6 0 ppublish 28378441 10.1002/acr.23230

EvidenceUpdates2018

86. Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis 28950421 2017 12 27 2326-5205 70 1 2018 Jan Arthritis & rheumatology (Hoboken, N.J.) Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis. 40-48 10.1002/art.40336 SB5 is a biosimilar agent for adalimumab (ADA). The aim of this study was to evaluate (...) the efficacy, pharmacokinetics (PK), safety, and immunogenicity of SB5 in comparison with reference ADA in patients with rheumatoid arthritis (RA). In this phase III, randomized, double-blind, parallel-group study, patients with moderately to severely active RA despite treatment with methotrexate were randomized 1:1 to receive SB5 or reference ADA at a dosage of 40 mg subcutaneously every other week. The primary efficacy end point was the response rate based on the American College of Rheumatology 20

EvidenceUpdates2018

87. Relationship between cartilage oligomeric matrix protein (COMP) and rheumatoid arthritis severity

Relationship between cartilage oligomeric matrix protein (COMP) and rheumatoid arthritis severity Electronic Physician (ISSN: 2008-5842) http://www.ephysician.ir December 2017, Volume: 9, Issue: 12, Pages: 5940-5947, DOI: http://dx.doi.org/10.19082/5940 Corresponding author: Assistant Professor Dr. Mandana Khodashahi, Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Tel: +98.9153023711, Email: Khodashahimn@mums.ac.ir Received: May 31, 2017, Accepted (...) or adaptations are made. Page 5940 Relationship between cartilage oligomeric matrix protein (COMP) and rheumatoid arthritis severity Massoud Saghafi 1 , Mandana Khodashahi 2 , Nayyereh Saadati 3 , Azita Azarian 4 , Zahra Rezaieyazdi 1 , Maryam Salehi 5,6 , Maryam Sahebari 3 1 MD of Rheumatology, Professor, Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran 2 MD of Rheumatology, Assistant Professor, Rheumatic Diseases Research Center, Mashhad University of Medical

Electronic physician2017 Full Text: Link to full Text with Trip Pro

88. Usability and Patient Preference Phase 3 Study of the Sarilumab Pen in Patients with Active Moderate-to-Severe Rheumatoid Arthritis

Usability and Patient Preference Phase 3 Study of the Sarilumab Pen in Patients with Active Moderate-to-Severe Rheumatoid Arthritis ORIGINAL RESEARCH Usability and Patient Preference Phase 3 Study oftheSarilumabPeninPatientswithActiveModerate- to-Severe Rheumatoid Arthritis Alan Kivitz . Lydie Baret-Cormel . Hubert van Hoogstraten . Sheldon Wang . Janie Parrino . Christine Xu . Marina Stanislav Received: October 25, 2017/Published online: December 5, 2017 The Author(s) 2017. This article (...) is an open access publication ABSTRACT Introduction: Sarilumab is a human mono- clonal antibody that blocks the interleukin-6 receptor alpha (IL-6Ra). The phase 3 SARIL-RA- EASY study (EASY) assessed the robustness of an autoinjector (pen) for administering sarilumab when used by adults with active moderate-to- severe rheumatoid arthritis (RA) who are can- didates for anti-IL-6R therapy in an unsuper- vised real-world setting. Methods: EASY was a 12-week, multicenter, randomized,open-label,parallel

Rheumatology and therapy2017 Full Text: Link to full Text with Trip Pro

89. A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United States

A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United States ORIGINAL RESEARCH A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United States Christina A. Spivey . Jenny Grif?th . Cameron Kaplan . Arnold Postlethwaite . Arijit Ganguli . Junling Wang Received: September 15, 2017/Published online: December 4, 2017 (...) The Author(s) 2017. This article is an open access publication ABSTRACT Introduction: Understanding the effects of corticosteroid utilization prior to initiation of biologic disease-modifying antirheumatic drugs (DMARDs) can inform decision-makers on the appropriateuseofthesemedications.Thisstudy examined treatment patterns and associated burden of corticosteroid utilization before ini- tiation of biologic DMARDs among rheumatoid arthritis (RA) patients. Methods: A retrospective analysis was con- ducted

Rheumatology and therapy2017 Full Text: Link to full Text with Trip Pro

90. The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis

The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found (...) . Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} There is some support for treat to target in rheumatoid arthritis, particularly in early stages, or for patients with disease duration < 5 years; however, it remains unclear which elements are important. {{author}} {{($index , , , , , , , , & . Allan Wailoo 1, * , Emma S Hock 1 , Matt Stevenson 1

NIHR HTA programme2017

91. Sirukumab (Plivensia) - rheumatoid arthritis

Sirukumab (Plivensia) - rheumatoid arthritis 26 October 2017 Dr. Tomas Salmonson Chair of Committee for Medicinal Products for Human Use European Medicines Agency 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Subject: Withdrawal of Plivensia (sirukumab), 50 mg, solution for injection, pre-filled syringe and pre-filled pen - EMEA/H/C/004165/0000 Dear Dr. Salmonson We would like to inform you that, at this point of time, Janssen-Cilag International NV has taken the decision (...) to withdraw the application for Marketing Authorisation of Plivensia (sirukumab), 50 mg, solution for injection, pre-filled syringe and pre-filled pen, which was intended to be used for the treatment of moderately to severely active rheumatoid arthritis in adult patients. This withdrawal is based on the following reason: The Company made a global strategic decision to prioritize other assets in our portfolio, given the need for additional clinical data that would result in significant delays to patient

European Medicines Agency - EPARs2017

92. Adalimumab (Cyltezo) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Hidradenitis Suppurativa, Psoriasis, Ankylosing Spondylitis, Uveitis

Adalimumab (Cyltezo) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Hidradenitis Suppurativa, Psoriasis, Ankylosing Spondylitis, Uveitis

European Medicines Agency - EPARs2017

94. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis

Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis 29187350 2017 11 30 1468-2060 2017 Nov 29 Annals of the rheumatic diseases Ann. Rheum. Dis. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis (...) . annrheumdis-2017-212423 10.1136/annrheumdis-2017-212423 To assess the risk of losing remission, low disease activity (LDA) or radiographic progression in the case of (1) discontinuing or (2) tapering doses of biological disease-modifying antirheumatic drugs (bDMARDs) compared with continuation of the initial treatment regimen in rheumatoid arthritis (RA) patients with remission or LDA. A systematic literature analysis was carried out through May 2017 on the PubMed, Embase, Cochrane and international

EvidenceUpdates2017

95. Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis 28968862 2017 10 02 1462-0332 2017 Aug 16 Rheumatology (Oxford, England) Rheumatology (Oxford) Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure (...) : results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. 10.1093/rheumatology/kex304 Both TNF inhibitors (TNFi) and rituximab (RTX), a B-cell depleting biologic, can disrupt the immune system in RA. RTX is licensed in Europe for use following TNFi failure. However, safety data on serious infections (SIs) are scarce for RTX in daily practice. This analysis aims to compare the risk of SIs in the first year after a switch to either TNFi or RTX in patients who have

EvidenceUpdates2017

96. Venous thromboembolism and risk of cancer in patients with rheumatoid arthritis

Venous thromboembolism and risk of cancer in patients with rheumatoid arthritis 28913891 2017 12 05 1538-7836 15 12 2017 Dec Journal of thrombosis and haemostasis : JTH J. Thromb. Haemost. Venous thromboembolism and risk of cancer in patients with rheumatoid arthritis. 2325-2332 10.1111/jth.13846 Essentials Can venous thromboembolism (VTE) in rheumatoid arthritis (RA) patients be marker of cancer? RA patients with VTE and comparison cohorts from population-based registries were compared (...) . Increased risk of cancer in RA patients with VTE during the first year of VTE was observed. Risk of cancer in RA patients was increased also during the longer period following VTE. Background It is unknown whether venous thromboembolism (VTE) in rheumatoid arthritis (RA) patients can be a marker of occult cancer. Objectives To examine risk of cancer subsequent to VTE among RA patients compared with risk of cancer in an RA cohort without VTE and in a general population without RA and without VTE

EvidenceUpdates2017

97. Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study

Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study ORIGINAL RESEARCH Secukinumab in Active Rheumatoid Arthritis afterAnti-TNFaTherapy:ARandomized,Double-Blind Placebo-Controlled Phase 3 Study Hasan Tahir . Atul Deodhar . Mark Genovese . Tsutomu Takeuchi . Jacob Aelion . Filip Van den Bosch . Sibylle Haemmerle . Hanno B. Richards Received: July 12, 2017 / Published online: November 14, 2017 The Author(s) 2017 (...) . This article is an open access publication ABSTRACT Introduction: ‘REASSURE’ (NCT01377012), a phase 3 study, evaluated the ef?cacy and safety of secukinumab in patients with active rheumatoid arthritis (RA) who had an inadequate response to, or intolerance of, tumor necrosis factor inhibitors (TNF-inhibitors). Methods: A total of 637 patients were random- ized (1:1:1) to receive intravenous secukinumab 10 mg/kg (baseline, weeks 2 and 4) followed by subcutaneous secukinumab 150 mg or 75 mg every 4 weeks

Rheumatology and therapy2017 Full Text: Link to full Text with Trip Pro

98. Physical activity and sedentary behavior in patients with systemic lupus erythematosus and rheumatoid arthritis

Physical activity and sedentary behavior in patients with systemic lupus erythematosus and rheumatoid arthritis © 2017 Legge et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses (...) Access Full T ext Article http://dx.doi.org/10.2147/OARRR.S148376 Physical activity and sedentary behavior in patients with systemic lupus erythematosus and rheumatoid arthritis Alexandra Legge 1 Chris Blanchard 1 John G Hanly 2,3 1 Department of Medicine, 2 Division of Rheumatology, Department of Medicine, 3 Department of Pathology, Dalhousie University and Queen Elizabeth II Health Sciences Center, Halifax, NS, Canada Objective: Patients with systemic lupus erythematosus (SLE) and rheumatoid

Open access rheumatology : research and reviews2017 Full Text: Link to full Text with Trip Pro

99. Mortality in Italian patients with rheumatoid arthritis: evidence for a low mortality rate from cancer and infections in patients followed up at a tertiary center

Mortality in Italian patients with rheumatoid arthritis: evidence for a low mortality rate from cancer and infections in patients followed up at a tertiary center 29138606 2018 11 13 1179-156X 9 2017 Open access rheumatology : research and reviews Open Access Rheumatol Mortality in Italian patients with rheumatoid arthritis: evidence for a low mortality rate from cancer and infections in patients followed up at a tertiary center. 185-189 10.2147/OARRR.S148270 Mortality in patients (...) with rheumatoid arthritis (RA) has never been investigated in Italy. This study is devoted to investigating all the distinct causes of mortality in Italian RA patients. Clinical charts of patients consecutively admitted to an Italian tertiary center, from January 1, 2008 to December 31, 2014, were reviewed. Mortality rates (incidence mortality rate [IMR] and standardized mortality rate [SMR]) and causes of death as assessed at December 31, 2015, were registered. Mortality rates detected in our series were

Open access rheumatology : research and reviews2017 Full Text: Link to full Text with Trip Pro

100. A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis

A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis 28666080 2017 06 30 2017 10 10 2017 11 02 2326-5205 69 10 2017 Oct Arthritis & rheumatology (Hoboken, N.J.) A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. 1937-1948 10.1002/art.40196 In disease (...) -modifying antirheumatic drug-naive patients with early rheumatoid arthritis (RA) who had achieved sustained low disease activity (a Disease Activity Score in 28 joints using the erythrocyte sedimentation rate of ≤3.2 at both week 40 and week 52) after 1 year of treatment with certolizumab pegol (CZP) at a standard dose (200 mg every 2 weeks plus optimized methotrexate [MTX]), we evaluated whether continuation of CZP treatment at a standard dose or at a reduced frequency (200 mg every 4 weeks plus MTX) was superior to stopping

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro